Dopamine agonists have been shown to be effective in delaying levodopa-induced dyskinesia in early Parkinson disease, but intermittent administration of short-acting dopaminergic agents can predispose Parkinson disease patients to motor fluctuations. Rotigotine, a non-ergot dopamine D2 agonist, has antiparkinsonian effects when infused intravenously, and a transdermal preparation is now available as rotigotine constant delivery system (CDS), which allows a constant delivery of the drug. This is a significant development in the treatment of Parkinson disease. In addition to an improved safety profile and symptomatic effectiveness, transdermal rotigotine can simplify treatment for physicians as well as patients. It is particularly useful for patients with dysphagia who have difficulty swallowing oral medications. It was approved in the United States by the Food and Drug Administration in 2007.